Therapist-guided vs Self-guided CBT for AD: Non-inferiority Trial

NACompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

December 5, 2023

Study Completion Date

October 1, 2024

Conditions
Atopic Dermatitis
Interventions
BEHAVIORAL

Therapist-guided cognitive behavioral therapy administered online

This intervention consists of 10 modules of education and interventions and lasts 12 weeks. An introduction provides information about CBT and AD. Step by step, the participants are introduced to the proposed active treatment components: mindfulness training, and exposure with response prevention. Through this whole process, the participant is guided by a therapist. The therapist may be contacted through a secure internet platform at any time and responds within 48 hours. Participants reads the education material, construct exercises to perform, describes their progress in homework assignments, and receives feedback from their therapist.

BEHAVIORAL

Self-guided digital intervention based on cognitive behavioral therapy

Participants will access a digital platform, read information, and perform exercises in their everyday life. The main treatment components are mindfulness and exposure with response prevention, with a specific focus on itch. Participants will be able to practice mindfulness with the help of instructions and examples. Participants will receive detailed instructions and guidance, and get to choose exposure exercises from a long list of examples. Participants will also be free to create their own relevant exposure situations within the intervention. Digital self-care consists of 8 modules. The only active interventions, mindfulness and exposure are introduced week 1 and 2, respectively. From week 3-7, no new interventions are introduced and participants are advised to continue practicing the interventions, but there is a new theme of education each week, to act as inspiration for exercises. The last 4 weeks, the participant is merely advised to continue practice.

Trial Locations (1)

11364

Centre for psychatry research, Stockholm

All Listed Sponsors
collaborator

Karolinska University Hospital

OTHER

lead

Karolinska Institutet

OTHER